Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
b'SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit.
- b'SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Oncology Innovation Summit.
- The Company\xe2\x80\x99s pipeline consists of small molecule drug candidates that target cancer signaling pathways.
- Kura is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations.
- For additional information about Kura, please visit the Company\xe2\x80\x99s website at www.kuraoncology.com .\n'